evodiamine has been researched along with Pancreatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Hong, Z; Jamshed, MB; Liao, Y; Tong, H; Wang, J; Wang, Z; Zhang, Q; Zheng, P; Zhou, B | 1 |
| Chen, H; Guo, HC; Lin, SZ; Liu, DL; Liu, HB; Ni, ZL; Tong, HF; Wang, ZH; Wei, WT | 1 |
2 other study(ies) available for evodiamine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Humans; Mice; Mice, Nude; Microtubule-Associated Proteins; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; NF-kappa B; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Quinazolines; Signal Transduction | 2012 |